Human CK-13/KRT13(CytokeRatin 13) ELISA Kit

Obstructive jaundice caused by metastasis of lung cancer to distal common bile duct (CBD) is extremely rare. Here, we report a 70-year-old man presented with progressive jaundice and generalized weakness for 1 month. He had a medical history of stage IIB (pT2N1M0) lung adenocarcinoma, for which he had undergone surgical treatment and subsequent adjuvant chemotherapy 3 years ago. Endoscopic retrograde cholangiopancreatography (ERCP) revealed a distal CBD stricture. Histopathological examination of the biopsy specimen taken from the stricture site demonstrated adenocarcinoma with positive for cytokeratin-7 and thyroid transcription factor-1 on immunohistochemistry. The findings confirmed the diagnosis of metastasis of recurrent lung adenocarcinoma to the CBD. The patient's jaundice improved after insertion of an endoscopic retrograde bile duct (ERBD) drainage plastic stent at the time of ERCP. He was then started on target therapy with afatinib after discharge. The ERBD stent was removed 3 months later. He had remained in stable condition without jaundice during the 1-year follow-up period. In conclusion, obstructive jaundice caused by metastatic adenocarcinoma to the CBD is a rare manifestation of lung cancer. An accurate diagnosis is crucial in further treatment for such a patient.

Objective To investigate the circulating tumour cells (CTCs) capture abilities of two technologies that are not dependent on cell-surface marker expression: a selection-free platform [AccuCyte(R)-CyteFinder(R) system (Rarecyte)] and a size-based platform [fluid-assisted separation technology (FAST)]. In addition, the combination of the two systems to more completely assess CTCs was investigated. Patients and methods In all, 28 patients with metastatic prostate cancer were included. Two 6 mL peripheral blood samples were taken from each patient at the same time-point. The samples were then subjected to the two different technology platforms in parallel. An additional group of samples was acquired by applying the waste chamber material from the FAST-group tests (flow-through that goes through the FAST filter membrane) to the Rarecyte system for the detection any CTCs that were not captured by FAST. Results The three groups had significantly different putative CTC-positive tests, with positive rates of 29% for Rarecyte, 57% for FAST, and 79% for the combination. We also assessed CTC phenotype: 56.6% of the CTCs were cytokeratin (CK)+/epithelial cell adhesion molecule (EpCAM)-, 3.1% were CK-/EpCAM+, and 40.3% were CK+/EPCAM+. The captured CTCs diameter ranged from 5.2 to 16.9 mu m. The mean CTC size from the FAST waste chamber was significantly smaller. The diameters for each of the phenotypic groups were significantly different. Conclusions These data highlight disparities in the positive rates and enumerated CTC numbers detected by the two techniques. Notably, the combination of the two technologies resulted in the highest CTC-capture rates. Smaller CTCs were more likely to be missed by the FAST as they passed through the filter system. Sizes of CTCs varied with different cell surface marker phenotypes.